Promoter holding
64.27%
KP
Kee Pharma Limited - Due diligence report
A 360° intelligence report on Kee Pharma Limited: trust score, financial health, credit view, compliance, directors, growth and distress sig…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Kee Pharma Limited — 360° Intelligence Report
Generated from MCA filings & public records62/100
Trust Score
Moderate
Kee Pharma Limited is assessed as Moderate with a Trust Score of 62/100. Kee Pharma Limited is an active public limited indian non-government company incorporated in 1991, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.
Report generated on 15 Jul 2026 from the latest processed filings. Kee Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
62/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
38/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
45/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
20/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 20/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
- Open charges exceed net worth - secured lenders rank ahead.
- Elevated gearing (D/E 38%).
Charges position: 12 open (9.50 cr) · 1 satisfied (4.50 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Indian Bank | 6 | 48.0 cr |
| State Bank Of India | 1 | 48.0 cr |
| Nidian Bank | 3 | 48.0 cr |
| Hsidc | 1 | 48.0 cr |
| Haryana State Industrial Development Cor. Ltd. | 1 | 48.0 cr |
| Ge Capital Services India | 1 | 48.0 cr |
Compliance Score: 38/100 Caution Indicated
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Flagged by authority: EPFO.
- Litigation present in 4 court forum(s).
- 9 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ANIL MOTIHAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HARINDER MOTIHAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANIL MOTIHAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANOJ KUMAR MISHRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MOHIT S NIGAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NATASHA GOYAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
3
Group entities
3
Capital events
1 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Kee Diagnostics Private Limited | Subsidiary Company | 74.00% |
| Kee Healthcare Private Limited | Subsidiary Company | 74.00% |
| Helvetica Industries Private Limited | Subsidiary Company | 74.00% |
Key managerial personnel: ANIL MOTIHAR (Managing Director) · ANIL MOTIHAR (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 65 · Distress 75
Growth signals & trust indicators
Steady revenue growth: +1.42 over 4 year(s).
EPFO headcount growing - hiring signal.
Operating for 35+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Losses deepening year-on-year.
Compliance score is weak (38/100).
12 open charge(s) registered - assets are encumbered.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence56/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment32/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 12 open charge(s) of 9.50 cr already registered.
- Compliance gaps should be priced into terms.
Investor view57/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events15 Dec 2025
Director appointed
MOHIT S NIGAM (Additional Director)
28 Sep 2025
Director ceased
NATASHA GOYAL
22 Jul 2025
Director appointed
NATASHA GOYAL (Director)
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
03 Apr 2019
Director appointed
ANIL MOTIHAR (CFO)
13 Sep 2018
Securities allotted
3904800 Equity Shares - 3.90 cr raised
30 Sep 2016
Director ceased
HARINDER MOTIHAR
31 Dec 2015
Director appointed
HARINDER MOTIHAR (Director)
Director ceased
AJIT RAMRAKHA BHASKAR
30 Sep 2015
Director ceased
VARUN MOTIHAR
05 Nov 2014
Director ceased
KAPIL KOHLI
12 Oct 2010
Charge satisfied
State Bank Of India
01 Apr 2010
Director ceased
ANIL MOTIHAR
15 Nov 2009
Director appointed
MANOJ KUMAR MISHRA (Company Secretary)
10
Key Observations
Auto-generated from the data aboveRevenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
6 active director(s) / partner(s); board looks stable and experienced.
9 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 3 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Mvl Medisynth Private Limited | U74999PN2011PTC174672 | Solapur North, Maharashtra, India |
| Padmavati Resins Private Limited | U24132PN2007PTC130621 | Pune, Maharashtra, India |
| United Descaler Private Limited | U24100DL2013PTC256572 | New Delhi, Delhi, India |
| Wipro Consumer And Personal Care Private Limited | U36999KA2020PTC135719 | Bangalore, Karnataka, India |
| Vantech Chemicals Ltd. | U24110TG1988PLC009277 | Andhra Pradesh, Telangana, India |
| Aravali Crop Science Limited | U24290DL2021PLC384380 | Delhi, Delhi, India |
| Surfactants And Allied Chemicals Private Limited | U24111TN1985PTC012282 | Chennai, Tamil Nadu, India |
| Cherry Paints And Polymers Pvt Ltd | U24114MP1995PTC009109 | Indore, Madhya Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Kee Pharma Limited before audits and certifications: compliance score 38/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Kee Pharma Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 20/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 65/100, margin trends, ownership structure and peer set for Kee Pharma Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 62/100, distress signals and MSME payment-delay disclosures - know whether Kee Pharma Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Kee Pharma Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Kee Pharma Limited an active company?
Kee Pharma Limited has MCA status “Active” with a compliance score of 38/100 (Caution Indicated).
Is Kee Pharma Limited financially healthy?
Kee Pharma Limited has a Financial Health Score of 45/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Kee Pharma Limited?
Its overall Trust Score is 62/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Kee Pharma Limited?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 6 active director(s) are on record.
Does Kee Pharma Limited have loans or charges against its assets?
12 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Kee Pharma Limited up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 38/100 (Caution Indicated).
Is it risky to lend to Kee Pharma Limited?
Its Credit Risk Score is 20/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
